FTRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Fortrea Holdings Inc (FTRE) is not a strong buy at the moment given the investor's long-term strategy and beginner knowledge level. The company's financial performance shows declining revenue and net income, and while there are some positive analyst upgrades and price target increases, the stock lacks clear near-term catalysts for significant growth. Additionally, technical indicators and options sentiment do not strongly support a bullish outlook. Holding the stock or waiting for further clarity on its financial recovery and market conditions would be more prudent.
The technical indicators for FTRE are neutral to slightly bearish. The MACD histogram is negative (-0.113) and contracting, RSI is neutral at 40.539, and moving averages are converging. The stock is trading near its pivot level of 10.294, with resistance at 11.184 and support at 9.404. These indicators suggest limited momentum and no strong trend direction.
Several analysts have upgraded the stock recently, with price targets ranging from $15 to $25, citing improving execution under new leadership, commercial momentum, and potential margin recovery. The biopharma cycle acceleration and deleveraging are also seen as positives.
Q4 2025 financial results showed a 5.2% YoY revenue decline and a 46.9% drop in net income. The company missed EPS expectations, and FY26 revenue forecasts are below expectations. Hedge funds are selling the stock, with a 182.65% increase in selling activity last quarter. Additionally, there are no recent congress trades or significant insider activity to suggest confidence in the stock.
In Q4 2025, Fortrea reported revenue of $660.5 million, down 5.24% YoY, and a net income loss of $32.5 million, down 46.9% YoY. EPS improved significantly to -10.81, up 1489.71% YoY, but gross margin declined to 16.93%, down 1.74% YoY. The financials indicate ongoing challenges in revenue growth and profitability.
Analysts have shown mixed to positive sentiment. Recent upgrades include Truist (Buy, $22 target), Evercore ISI (Outperform, $25 target), and Citi (Buy, $21 target). However, there are also Neutral ratings from Mizuho and TD Cowen, reflecting cautious optimism. Analysts highlight improving execution, margin recovery, and biopharma cycle acceleration as positives, but also note challenges in healthcare utilization growth and FY26 revenue expectations.
